Eysuvis is a drug owned by Alcon Laboratories Inc. It is protected by 17 US drug patents filed from 2021 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 03, 2033. Details of Eysuvis's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11219596 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10857096 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10940108 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US9827191 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US12115246 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US10688045 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10646436 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(7 years from now) | Active |
| US11596599 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10945948 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
| US10993908 | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eysuvis's patents.
Latest Legal Activities on Eysuvis's Patents
Given below is the list of recent legal activities going on the following patents of Eysuvis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9532955 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857096 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US9532955 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US10058511 |
| Correspondence Address Change Critical | 04 Mar, 2024 | US11872318 |
| Recordation of Patent Grant Mailed Critical | 16 Jan, 2024 | US11872318 |
| Email Notification Critical | 16 Jan, 2024 | US11872318 |
| Patent eGrant Notification | 16 Jan, 2024 | US11872318 |
| Mail Patent eGrant Notification | 16 Jan, 2024 | US11872318 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Jan, 2024 | US11872318 |
FDA has granted several exclusivities to Eysuvis. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Eysuvis, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Eysuvis.
Exclusivity Information
Eysuvis holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Eysuvis's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 26, 2023 |
US patents provide insights into the exclusivity only within the United States, but Eysuvis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eysuvis's family patents as well as insights into ongoing legal events on those patents.
Eysuvis's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eysuvis's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 03, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eysuvis Generic API suppliers:
Loteprednol Etabonate is the generic name for the brand Eysuvis. 6 different companies have already filed for the generic of Eysuvis, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Eysuvis's generic
Alternative Brands for Eysuvis
Eysuvis which is used for treating dry eye condition., has several other brand drugs in the same treatment category and using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alcon Labs Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Loteprednol Etabonate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Bausch And Lomb |
| |||
| Bausch And Lomb Inc |
| |||
| Pharmos |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Eysuvis's active ingredient. Check the complete list of approved generic manufacturers for Eysuvis
About Eysuvis
Eysuvis is a drug owned by Alcon Laboratories Inc. It is used for treating dry eye condition. Eysuvis uses Loteprednol Etabonate as an active ingredient. Eysuvis was launched by Alcon Labs Inc in 2020.
Approval Date:
Eysuvis was approved by FDA for market use on 26 October, 2020.
Active Ingredient:
Eysuvis uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient
Treatment:
Eysuvis is used for treating dry eye condition.
Dosage:
Eysuvis is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.25% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |